154 related articles for article (PubMed ID: 30074418)
1. Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.
Kristensen A; Solheim TS; Fløtten Ø; Grønberg BH
Acta Oncol; 2018 Nov; 57(11):1574-1579. PubMed ID: 30074418
[TBL] [Abstract][Full Text] [Related]
2. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
[TBL] [Abstract][Full Text] [Related]
3. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Grønberg BH; Sundstrøm S; Kaasa S; Bremnes RM; Fløtten O; Amundsen T; Hjelde HH; Plessen Cv; Jordhøy M
Eur J Cancer; 2010 Aug; 46(12):2225-34. PubMed ID: 20471248
[TBL] [Abstract][Full Text] [Related]
4. Measurement of health-related quality of life during chemotherapy - the importance of timing.
Kristensen A; Solheim TS; Amundsen T; Hjelde HH; Kaasa S; Sørhaug S; Grønberg BH
Acta Oncol; 2017 May; 56(5):737-745. PubMed ID: 28117614
[TBL] [Abstract][Full Text] [Related]
5. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy and quality of life in NSCLC PS 2 patients.
Helbekkmo N; Strøm HH; Sundstrøm SH; Aasebø U; Von Plessen C; Bremnes RM;
Acta Oncol; 2009; 48(7):1019-25. PubMed ID: 19274496
[TBL] [Abstract][Full Text] [Related]
7. Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Ediebah DE; Coens C; Zikos E; Quinten C; Ringash J; King MT; Schmucker von Koch J; Gotay C; Greimel E; Flechtner H; Weis J; Reeve BB; Smit EF; Taphoorn MJ; Bottomley A
Br J Cancer; 2014 May; 110(10):2427-33. PubMed ID: 24743709
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
Helbekkmo N; Sundstrøm SH; Aasebø U; Brunsvig PF; von Plessen C; Hjelde HH; Garpestad OK; Bailey A; Bremnes RM;
Br J Cancer; 2007 Aug; 97(3):283-9. PubMed ID: 17595658
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Fiteni F; Anota A; Bonnetain F; Oster JP; Pichon E; Wislez M; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Molinier O; Dansin E; Poudenx M; Milleron B; Morin F; Zalcman G; Quoix E; Westeel V
Eur Respir J; 2016 Sep; 48(3):861-72. PubMed ID: 27338193
[TBL] [Abstract][Full Text] [Related]
10. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer.
Sjøblom B; Benth JŠ; Grønberg BH; Baracos VE; Sawyer MB; Fløtten Ø; Hjermstad MJ; Aass N; Jordhøy M
Clin Lung Cancer; 2017 Mar; 18(2):e129-e136. PubMed ID: 27825639
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.
Fløtten Ø; Grønberg BH; Bremnes R; Amundsen T; Sundstrøm S; Rolke H; Hornslien K; Wentzel-Larsen T; Aasebø U; von Plessen C
Br J Cancer; 2012 Jul; 107(3):442-7. PubMed ID: 22759880
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
de Castria TB; da Silva EM; Gois AF; Riera R
Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
[TBL] [Abstract][Full Text] [Related]
14. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Hasegawa Y; Kawaguchi T; Kubo A; Ando M; Shiraishi J; Isa S; Tsuji T; Tsujino K; Ou SH; Nakagawa K; Takada M
J Thorac Oncol; 2011 Nov; 6(11):1881-8. PubMed ID: 21841503
[TBL] [Abstract][Full Text] [Related]
15. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.
von Plessen C; Bergman B; Andresen O; Bremnes RM; Sundstrom S; Gilleryd M; Stephens R; Vilsvik J; Aasebo U; Sorenson S
Br J Cancer; 2006 Oct; 95(8):966-73. PubMed ID: 17047644
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
Shi X; Yu XM; Zhang YP; Zhao J
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
[TBL] [Abstract][Full Text] [Related]
17. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer.
Horvath L; Boyer M; Clarke S; Beale P; Beith J; Underhill C; Stockler M; Bishop J
Lung Cancer; 2001 May; 32(2):173-8. PubMed ID: 11325488
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
